- Trial phase
- Approved
- Time to market
- Already approved but commercially unavailable; GSK is working on a relaunch with no confirmed date as of October 2026. Shortage tracking shows 0% pharmacy availability.
- Why 4/10
- BREXAFEMME is already FDA-approved (2021, 2022) with no pending regulatory decision, its defining binary catalysts are in the past. The next event is GSK's commercial relaunch, which has no confirmed date, and SCYX is now a multi-asset pipeline company with SCY-247 and SCY-770 driving future catalysts.
There is no hard, dated binary catalyst for BREXAFEMME itself, it is already approved and the commercial relaunch by GSK has no confirmed timeline. SCYX investors should watch the Q3 2026 earnings call (estimated Nov 11) for any GSK relaunch updates, and the start of SCY-770 Phase 2 PoC in ADPKD (expected Q4 2026) as the company's next value-driving pipeline catalyst.
Price Chart
Executive Summary
BREXAFEMME (ibrexafungerp) is an oral, first-in-class triterpenoid antifungal approved by the FDA in June 2021 for vulvovaginal candidiasis (VVC) and in November 2022 for recurrent VVC. Scynexis (SCYX) licensed global rights to GSK in May 2023 for $90M upfront plus up to $503M in milestones and tiered royalties. The drug has been commercially unavailable since a September 2023 voluntary recall over cross-contamination concerns, followed by a 19-month FDA clinical hold that was lifted in 2025. The NDA was transferred to GSK in November 2025, and as of late October 2026, BREXAFEMME remains off pharmacy shelves with no confirmed relaunch date. SCYX has since pivoted to a clinical-stage pipeline (SCY-247 antifungal, SCY-770 ADPKD drug) and is no longer single-asset dependent on BREXAFEMME.
How It Works
BREXAFEMME is an oral antifungal pill that kills Candida yeast by disrupting the fungal cell wall, the first drug in a new antifungal class (triterpenoids) approved in over 20 years. It is taken by mouth as a one-day treatment for vaginal yeast infections, unlike older azole antifungals that work differently and face growing resistance.
Trial Status
FDA-approved June 2021 for vulvovaginal candidiasis (VVC) and November 2022 for reduction in incidence of recurrent VVC. The drug is currently off the market due to a voluntary recall (September 2023) and manufacturing remediation. A Phase 3 MARIO study was placed on clinical hold for 19 months (Oct 2023-May 2025) but dosing has resumed.
The Two-Sided Case
Upcoming Catalysts
- GSK BREXAFEMME commercial relaunch timeline (date TBD)
- SCYX Q3 2026 earnings call (estimated Nov 11, 2026), potential GSK relaunch updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Scynexis Press Release SCYX ·Originating report